Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2013

View Archived Issues

Mayo Clinic licenses patient-derived xenograft models of cancer to WuXi PharmaTech

Tricyclo-DNA oligonucleotides show promise for SMA and DMD

Swedish Orphan Biovitrum provides update on pipeline candidates

Daiichi Sankyo updates pipeline progress of second quarter of fiscal 2013

Biomarker predicts exacerbations in cystic fibrosis patients

AB Pharma and Zannan SciTech identify novel HCV NS5A inhibitors

First patient enrolled in Serodus' phase IIa trial of SER-100

Phase II trial of Zerenex in NDD-CKD meets all primary and key secondary endpoints

IDMC recommends continuation of Cel-Sci's pivotal trial of Multikine

Omeros reports data for OMS-721 from model of age-related macular degeneration

AEterna Zentaris submits NDA to FDA for macimorelin acetate

Five Prime Therapeutics licenses proprietary antibodies to ADC Therapeutics

Trophos completes pivotal phase II/III study of olesoxime in spinal muscular atrophy in Europe

Inducers of immune tolerance increased in cystic fibrosis airway neutrophils

Ajinomoto reports phase IIa results for AJM-300 in ulcerative colitis

Takeda reviews highlights of second quarter of fiscal 2013

GE Healthcare tests novel PET tracers for evaluating traumatic brain injury

Novogen and Yale University create joint venture to develop drugs for ovarian cancer

Prima Biomed grants CVac license to Neopharm for Israel

Researchers in the U.S. and Taiwan present new ganciclovir prodrugs

Cancer Research Technology reports novel CDK9 inhibitors for cancer

U.S. team synthesizes new anticancer agents

Novel arginase inhibitors synthesized by Mars

Biota Scientific Management discloses new NS5B inhibitors for HCV infection

Novo Nordisk presents pipeline developments of third quarter 2013

New phase II study investigates ADI-PEG-20 for relapsed or refractory AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...